Drug Discovery & Pharmaceuticals

RSS

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

From Enterprise Therapeutics Ltd 31 Jan 2024

New DNA-based vaccine can induce strong antibody response against SARS-CoV-2

Using a virus-like delivery particle made from DNA, researchers from MIT and the Ragon Institute of MGH, MIT, and Harvard have created a vaccine that can induce a strong antibody response against SARS-CoV-2.

30 Jan 2024

New study opens unprecedented opportunities for bioengineering vaccine adjuvants

A valuable molecule sourced from the soapbark tree and used as a key ingredient in vaccines, has been replicated in an alternative plant host for the first time, opening unprecedented opportunities for the vaccine industry.

26 Jan 2024

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

24 Jan 2024

C-Path's TRxA launches 2024 grants to boost next-gen therapeutics

Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe.

23 Jan 2024

Moffitt researchers develop novel reagent for efficient synthesis of sulfur-containing drug candidates

During the past decade, there has been significant development of new sulfur containing compounds that are used in various industries, including pharmaceuticals and agricultural products.

22 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Conscience's open science competition yields hits for new Parkinson's drugs

As part of its pioneering approach to drug discovery, the Canadian nonprofit Conscience announced today that its first open science competition has resulted in the identification of seven promising molecules, or "hits," that show potential for new, more effective drugs for familial Parkinson's disease.

16 Jan 2024

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.

13 Jan 2024

New compound effective against bacterial species resistant to multiple classes of existing antibiotics

Recent studies by Zampaloni et al. and Pahil et al. published in the journal Nature describe a novel method of inhibiting the growth of Gram-negative bacteria such as Acinetobacter using antibiotics consisting of macrocyclic peptides that target the bacterial protein bridge machinery that transports lipopolysaccharides from the cytoplasm to the outer membrane.

4 Jan 2024

New synthetic antibiotic found to be more effective than established drugs against 'superbugs'

A new synthetic antibiotic developed by University of Liverpool researchers is shown to be more effective than established drugs against 'superbugs' such as MRSA, a new study shows.

3 Jan 2024

Scripps scientists develop powerful method to find drug targets in live cells

Identifying new ways to target proteins involved in human diseases is a priority for many researchers around the world.

2 Jan 2024

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

28 Dec 2023

New method designs high-affinity, orally bioavailable peptides

For decades, a substantial number of proteins, vital for treating various diseases, have remained elusive to oral drug therapy.

28 Dec 2023

Degron Therapeutics announced as winner of AFCR's 2023 BRACE Award Venture Competition

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition.

27 Dec 2023

Researchers receive two grants to study tuberculosis drug development

Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis (TB) drug development.

26 Dec 2023

First new antibiotic class in decades discovered using explainable AI platform

Scientists have discovered one of the first new classes of antibiotics identified in the past 60 years, and the first discovered leveraging an AI-powered platform built around explainable deep learning.

20 Dec 2023

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system

Researchers investigated the anticancer effects of drugs targeting human tumor-associated macrophages (TAMs) in vivo. In humanized murine models, they tested the effectiveness of an antibody to human signal regulatory protein alpha (SIRPα) for cancer immunotherapy.

19 Dec 2023

Scientists crack the code for targeting cancer's 'death star' protein

Researchers at the Centre for Genomic Regulation in Barcelona, Spain, and the Wellcome Sanger Institute near Cambridge, UK, have comprehensively identified the allosteric control sites found in the protein KRAS.

18 Dec 2023